Tecartus Approved for Treatment of Mantle Cell Lymphoma
News Consumer News Tecartus Approved for Treatment of Mantle Cell Lymphoma MONDAY, July 27, 2020 — Tecartus (brexucabtagene autoleucel) received approval for the treatment of mantle cell lymphoma (MCL) in patients who have not responded to other treatment types or relapsed following treatment, the U.S. Food and Drug Administration announced Friday. Tecartus is a chimeric… Read More »